Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221405 | 0.87 | PDPK1 (0.43) | PDPK1LOXL2CYP2A6FBP1MEN1 | |
| SCHEMBL11402488 | 0.87 | PDPK1 (0.43) | PDPK1LOXL2CYP2A6FBP1MEN1 | |
| SCHEMBL11402984 | 0.87 | PTGES (0.44) | PDPK1LOXL2CYP2A6FBP1MEN1 | |
| SCHEMBL16111553 | 0.87 | PDPK1 (0.43) | PDPK1LOXL2CYP2A6FBP1MEN1 | |
| SCHEMBL27382644 | 0.81 | ALDH1A1 (0.46) | PDPK1MEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL28031696 | 0.81 | SMN1; SMN2 (0.42) | PDPK1LOXL2MEN1ALDH1A1KMT2A | |
| SCHEMBL11398327 | 0.81 | ALDH1A1 (0.41) | PDPK1LOXL2ALDH1A1GAA | |
| SCHEMBL30457805 | 0.78 | PDPK1 (0.53) | PDPK1CYP2A6FBP1MEN1ALDH1A1 | |
| SCHEMBL1565328 | 0.78 | PDPK1 (0.53) | PDPK1CYP2A6FBP1MEN1ALDH1A1 | |
| SCHEMBL31055003 | 0.77 | PDPK1 (0.52) | PDPK1LOXL2CYP2A6ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-7262204-B2 | Modulation of CCR4 function | AMGEN INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7144903-B2 | CCR4 antagonists | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1578341-A4 | MODULATION OF CCR4 FUNCTION | TULARIK INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1578341-A2 | MODULATION OF CCR4 FUNCTION | Tularik Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040039035-A1 | Modulation of CCR4 function | TULARIK INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030018022-A1 | Ccr4 antagonists | TULARIK INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002094264-A1 | CCR4 ANTAGONISTS | TULARIK INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020173524-A1 | Modulation of CCR4 function | TULARIK INC. (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002030358-A2 | MODULATION OF CCR4 FUNCTION | TULARIK INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-0377904-A2 | Agent against protozoae in insects | BAYER AG (DE) | 1990-07-18 | — | — | EP | disclosed |
| EP-0353526-A2 | Agent against fish parasites containing triazinedione derivatives | BAYER AG (DE) | 1990-02-07 | — | — | EP | disclosed |
| EP-0330041-A2 | Substituted 1,2,4-trazine diones, process for their synthesis and their use | BAYER AG (DE) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018022-A1 | Ccr4 antagonists | CCR4, CCR1, CCR3 | PDPK1 3710/4885LOXL2 1248/4885CYP2A6 1785/4885 |
| US-20020173524-A1 | Modulation of CCR4 function | CCR4, CCR1, CCR3 | PDPK1 3645/4885LOXL2 1280/4885CYP2A6 1674/4885 |
| US-20040039035-A1 | Modulation of CCR4 function | CCR4, CCR1, CCR3 | PDPK1 3645/4885LOXL2 1280/4885CYP2A6 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.